

In the Claims:

Please amend the claims as shown:

1. (Currently Amended) A peptide which comprises the following amino acid sequence (SEQ ID NO: 1)

Ser-Cys-Asn-Thr-Ala-Thr-Cys-Met-Thr-His-	10
Arg-Leu-Val-Gly-Leu-Leu-Ser-Arg-Ser-Gly-	20
Ser-Met-Val-Arg;Ser-Asn-Leu-Leu-Pro-Thr-	30
Lys-Met-Gly-Phe-Lys-Val-Phe-Gly	38

or an amino acid sequence where a part of the amino acids are deleted, substituted or added and has properties of (1) being expressed in central nervous system, (2) strongly acting on calcitonin receptors and (3) promoting the cAMP productivity of cells.

2. (Original) The peptide according to claim 1, wherein the peptide further has (4) a property of incorporation of sodium ion concentration-dependently, (5) a property of suppressing the incorporation of calcium ion and (6) a property of suppressing the cell proliferation.

3. (Previously Presented) The peptide according to claim 1, wherein the peptide has at least an amino acid sequence shown in SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 6, SEQ ID NO: 9, SEQ IS NO: 12, SEQ ID NO: 16 or SEQ ID NO: 19 of the Sequence Listing or an amino acid sequence where a part of amino acids are deleted, substituted or added.

4. (Previously Presented) The peptide according to claim 1, wherein the peptide is a peptide derived from mammals.

5. (Previously Presented) A gene which encodes the peptides according to claim 1.

6. (Previously Presented) The gene according to claim 5, wherein the gene has a nucleotide sequence of SEQ ID NO: 3, SEQ ID NO: 7, SEQ ID NO: 10, SEQ ID NO: 13, SEQ IS NO: 17 or SEQ ID NO: 20.

7. (Previously Presented) A pharmaceutical composition comprising the peptide according to claim 1 and a pharmaceutically acceptable carrier.

8. (Original) The pharmaceutical composition according to claim 7, wherein the pharmaceutical composition is a preventive/treating agent for osteoporosis, a preventive/treating agent for cancer, a diuretic agent, an appetite suppressing agent or an analgesic agent.

9. (Original) The pharmaceutical composition according to claim 7, wherein the pharmaceutical composition is a hypotensive agent or a drug which prevents restenosis after PTCA (percutaneous transluminal coronary angioplasty).

10. (Previously Presented) A method for treating a subject suffering from or susceptible to osteoporosis, comprising administering to the subject a peptide of claim 1.

11. (Previously Presented) The method of claim 10 wherein the subject is identified as suffering from osteoporosis and the peptide is administered to the identified subject.

12. (Previously Presented) A method for treating a subject suffering from or susceptible to cancer, comprising administering to the subject a peptide of claim 1.

13. (Previously Presented) The method of claim 12 wherein the subject is identified as suffering from cancer and the peptide is administered to the identified subject.

14. (Previously Presented) A method for treating a subject in need of a diuretic, comprising administering to the subject a peptide of claim 1.

15. (Previously Presented) The method of claim 14 wherein the subject is identified as being in need of a diuretic and the peptide is administered to the identified subject.

16. (Previously Presented) A method for treating a subject in need of an analgesic, comprising administering to the subject a peptide of claim 1.

17. (Previously Presented) The method of claim 16 wherein the subject is identified as being in need of an analgesic and the peptide is administered to the identified subject.

18. (Previously Presented) A method for treating a subject in need of an appetite suppressant agent, comprising administering to the subject a peptide of claim 1.

19. (Previously Presented) The method of claim 18 wherein the subject is identified as being in need of an appetite suppressant agent and the peptide is administered to the identified subject.

20. (Previously Presented) A method for treating a subject in need of a hypotensive agent, comprising administering to the subject a peptide of claim 1.

21. (Previously Presented) The method of claim 18 wherein the subject is identified as being in need of a hypotensive agent and the peptide is administered to the identified subject.

22. (Previously Presented) A method for treating a subject having undergone percutaneous transluminal coronary angioplasty, comprising administering to the subject a peptide of claim 1.

23. (Previously Presented) The method of claim 22 wherein the subject is identified as being in risk of restenosis following percutaneous transluminal coronary angioplasty and the peptide is administered to the identified subject.